Arcellx

Gilead (NASDAQ: GILD), a leading biopharmaceutical company, has announced an expansion of its 2022 partnership with Arcellx (NASDAQ: ACLX), a US-based biotechnology firm. The collaboration includes the in-licensing of ACLX-001, a multiple myeloma (MM) engineered cell therapy, and the extension of their CART-ddBCMA program to include lymphomas . Financial Terms…